BioNTech and Bristol Myers Squibb report encouraging interim data for lung cancer therapy
Interim Phase 2 data from the ROSETTA Lung-02 study shows high response rates for pumitamig in non-small cell lung cancer, while the Swiss bank lifts its price target to $135.
BioNTech SE and Bristol Myers Squibb Company announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial on May 30. The trial evaluated the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig in combination with chemotherapy for patients with previously untreated advanced non-small cell lung cancer.
The reported data indicated encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous non-small cell lung cancer subtypes. These results were consistent across all PD-L1 expression levels, suggesting a broad efficacy signal for the bispecific approach.
Solange Peters, M.D., Ph.D., Lead Investigator and Director of Oncology at the University Hospital of Lausanne in Switzerland, stated that the efficacy signal supports the continued investigation of pumitamig. Peters noted the robust responses across subtypes and PD-L1 levels, highlighting the potential for the therapy to deliver improved outcomes for a broad range of patients.
In a separate development regarding the company’s market valuation, UBS upgraded BioNTech SE to a Buy rating from Neutral on May 27. The Swiss bank raised its price target for the stock to $135 from $117, reflecting a more optimistic outlook on the company’s prospects.
The combination of positive clinical data and an analyst upgrade provides a dual catalyst for the biotechnology firm. The ROSETTA Lung-02 study remains a key component of BioNTech’s pipeline, with the interim results reinforcing the rationale for further development of pumitamig in the oncology space.
